Related Experiment Video
Updated: Jul 10, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Nephrogenic systemic fibrosis: center case review.
Thomas C Lauenstein1, Khalil Salman, Roger Morreira
1Department of Radiology, Emory University Hospital, Atlanta, Georgia 30322, USA.
Nephrogenic Systemic Fibrosis (NSF) is linked to gadolinium-based contrast agents (GBCAs), particularly Omniscan. Patients with severe renal insufficiency receiving GBCAs require careful monitoring for NSF development.
Area of Science:
- Nephrology
- Radiology
- Medical Imaging
Background:
- Nephrogenic Systemic Fibrosis (NSF) is a debilitating condition.
- Gadolinium-based contrast agents (GBCAs) are used in MRI.
- Patients with renal insufficiency are at higher risk.
Purpose of the Study:
- To analyze Nephrogenic Systemic Fibrosis (NSF) cases.
- To determine prior gadolinium-based contrast agent (GBCA) administration.
- To evaluate risk factors for NSF development.
Main Methods:
- Retrospective analysis of NSF cases.
- Cross-referencing pathology, MRI, dialysis, and medical records.
- Evaluation of laboratory data and concurrent medications in NSF patients compared to controls.
Main Results:
- Nine NSF cases identified between 2003-2007.
- All NSF patients received contrast-enhanced MRI prior to diagnosis.
- Prevalence of NSF in dialysis patients exposed to gadodiamide was 2.6%.
Conclusions:
- Findings support the association between gadodiamide and NSF.
- All NSF patients had severe renal insufficiency (GFR < 30 mL/minute).
- Average GBCA exposure was 71 mL over 2.9 administrations.
Related Concept Videos
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Acute Kidney Injury II: Pathophysiology
Nephrons
Chronic Kidney Disease III: Interprofessional Care